Geode Capital Management LLC Purchases 276,055 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Geode Capital Management LLC raised its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 9.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,166,480 shares of the company’s stock after purchasing an additional 276,055 shares during the quarter. Geode Capital Management LLC owned 1.42% of Sana Biotechnology worth $13,175,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SANA. FMR LLC grew its holdings in shares of Sana Biotechnology by 16.3% during the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after buying an additional 4,438,949 shares during the last quarter. Integral Health Asset Management LLC lifted its position in Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after acquiring an additional 220,000 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Sana Biotechnology by 11.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock valued at $4,359,000 after purchasing an additional 105,382 shares during the last quarter. State Street Corp increased its holdings in shares of Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after purchasing an additional 269,274 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after purchasing an additional 178,179 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Sana Biotechnology in a research note on Wednesday, November 27th.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $1.61 on Tuesday. Sana Biotechnology, Inc. has a one year low of $1.52 and a one year high of $12.00. The stock has a fifty day moving average of $2.68 and a 200 day moving average of $4.28. The stock has a market cap of $359.46 million, a PE ratio of -1.15 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. As a group, sell-side analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.